FDA wants restrictions on bone meds with calcitonin; Arena says DEA's not finished with Belviq;

@FiercePharma: Merck CEO's biggest accomplishment so far? Standing firm on R&D spending as $MRK got pounded, he tells AP: Report | Follow @FiercePharma

@EricPFierce: Happy anniversary, Bayer. A year after India granted first compulsory license for Nexavar, board rejects appeal. News | Follow @EricPFierce

> FDA reviewers highlighted a "plausible" risk of cancer with bone drugs containing calcitonin salmon and recommended their use be restricted to exclude osteoporosis patients. Report

> Arena Pharmaceuticals ($ARNA) said the Drug Enforcement Administration hasn't yet finalized the controlled substances designation on its yet-to-be-launched obesity drug Belviq. Report

> Elan ($ELN) will let stockholders share in the royalties from its multiple sclerosis drug Tysabri in an attempt to fend off a $6.5 billion buyout bid from RP Management. Report

> Private equity firm Warburg Pincus tapped a group of investment bankers to lead a Bausch + Lomb IPO that would raise as much as $1.5 billion. Report

> In the wake of safety scandals, Chinese officials have proposed a new, stronger agency to oversee the food and drug industries. Report

> Boehringer Ingelheim has teamed up with the online community PatientsLikeMe to help patients with idiopathic pulmonary fibrosis to monitor their health and connect with other patients. Report

Medical Device News

 @FierceMedDev: Special Report: Devicemakers plot paths out of CRM funk. Feature | Follow @FierceMedDev

 @MarkHFierce: Toshiba's medical equipment division is expanding in South Korea. Release | Follow @MarkHFierce

 @DamianFierce: Parexel says it's got its M&A eye on the Middle East and some small tech companies this year. Report | Follow @DamianFierce

> Stryker closes $764M deal for Chinese ortho giant. Article

> Toshiba Medical rolls out South Korean subsidiary. Story

Biotech News

 @FierceBiotech: Popular this weekend: Celgene's blockbuster dreams fade as apremilast PhIII fails to excite. Story | Follow @FierceBiotech

@JohnCFierce: Doctors declare "functional cure" of an infant infected with HIV--A first for an infant. More | Follow @JohnCFierce

@RyanMFierce: J&J backs startup effort tackling Big Data-driven disease models. More from FierceBiotechIT.com | Follow @RyanMFierce

> Merck KGaA fashions its 6th biotech from Serono R&D wreckage. News

> Elan woos investors with a special dividend plan for Tysabri. Item

> Novartis CEO Jimenez focuses R&D on the new blockbuster paradigm. Report

> Celgene's blockbuster dreams fade as apremalist PhIII fails to excite. Story

CRO News

> Trial sites say Biogen, Forest, Bayer are top sponsors. Item

> Covance allies with M2Gen for personalized medicine, cancer trials. News

> Particle Sciences teams with Chinese CRO on solubility. More

> Capsugel bets on drug delivery with Encap buy. Report

> Synteract goes global with Harrison buyout. Article

Biotech IT News

> Could playing mobile phone games help advance cancer cures? More

> GSK jumps new IT hurdles in 'real-world' test of blockbuster hopeful. Editor's Corner

> Accelrys marks Q4 growth as buyouts weigh on bottom line. Report

> Biocon chief prescribes new tech, analytics to treat R&D woes in pharma. Story

> What Facebook and Google billionaires could do for overlooked biotech brains. Item

And Finally... Doctors say they've cured an infant born with HIV by giving her a cocktail of available drugs shortly after birth. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.